Atea Historical Balance Sheet

AVIR Stock

USD 3.46 0.16 4.85%

Trend analysis of Atea Pharmaceuticals balance sheet accounts such as Other Current Liab of 20 M, Total Current Liabilities of 57 M or Total Stockholder Equity of 434.1 M provides information on Atea Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Atea Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Atea Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Atea Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Atea Pharmaceuticals is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Atea Stock, please use our How to Invest in Atea Pharmaceuticals guide.

About Atea Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Atea Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Atea Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Atea Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Atea currently owns. An asset can also be divided into two categories, current and non-current.

Atea Pharmaceuticals Balance Sheet Chart

At this time, Atea Pharmaceuticals' Property Plant And Equipment Gross is relatively stable compared to the past year. As of 11/27/2024, Accumulated Other Comprehensive Income is likely to grow to about 217.3 K, while Other Current Liabilities is likely to drop slightly above 20 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab Short Term Debt

Add Fundamental

Total Assets

Total assets refers to the total amount of Atea Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Atea Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Atea Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Atea Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Atea Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Atea Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Atea Stock, please use our How to Invest in Atea Pharmaceuticals guide.At this time, Atea Pharmaceuticals' Property Plant And Equipment Gross is relatively stable compared to the past year. As of 11/27/2024, Accumulated Other Comprehensive Income is likely to grow to about 217.3 K, while Other Current Liabilities is likely to drop slightly above 20 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	49.6M	14.4M	27.4M	20.0M
Total Assets	772.9M	666.7M	595.0M	541.8M

Other Current Liab Total Assets

Atea Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock
Total Assets		0.82	0.69	0.98	0.73	0.96	0.55	0.52	-0.89	-0.24	0.69	0.89	0.58	0.57	0.4	1.0	0.97	0.85	-0.98	0.99	0.95	0.39	0.98	0.57	1.0	0.97
Other Current Liab	0.82		0.32	0.87	0.83	0.87	0.39	0.1	-0.69	-0.05	0.91	0.69	0.43	0.43	0.24	0.83	0.83	0.76	-0.82	0.85	0.65	0.01	0.87	0.42	0.82	0.84
Total Current Liabilities	0.69	0.32		0.53	0.06	0.5	0.01	0.97	-0.72	-0.11	0.01	0.72	0.01	0.02	-0.04	0.69	0.56	0.48	-0.61	0.61	0.85	0.94	0.53	0.01	0.69	0.56
Total Stockholder Equity	0.98	0.87	0.53		0.84	0.99	0.64	0.34	-0.85	-0.24	0.8	0.84	0.67	0.66	0.49	0.98	0.98	0.86	-0.98	1.0	0.88	0.2	1.0	0.65	0.98	0.99
Other Liab	0.73	0.83	0.06	0.84		0.84	0.8	-0.17	-0.46	-0.43	0.93	0.45	0.83	0.84	0.4	0.73	0.79	0.76	-0.82	0.79	0.55	-0.29	0.84	0.83	0.73	0.83
Net Tangible Assets	0.96	0.87	0.5	0.99	0.84		0.66	0.32	-0.79	-0.3	0.84	0.79	0.68	0.68	0.44	0.96	0.99	0.85	-0.97	0.98	0.87	0.17	0.99	0.67	0.96	0.99
Property Plant And Equipment Net	0.55	0.39	0.01	0.64	0.8	0.66		-0.13	-0.25	-0.69	0.61	0.25	1.0	0.99	0.54	0.55	0.64	0.59	-0.67	0.6	0.47	-0.28	0.64	1.0	0.55	0.68
Current Deferred Revenue	0.52	0.1	0.97	0.34	-0.17	0.32	-0.13		-0.62	-0.03	-0.21	0.61	-0.14	-0.13	-0.08	0.52	0.39	0.3	-0.43	0.43	0.73	0.98	0.34	-0.14	0.52	0.37
Net Debt	-0.89	-0.69	-0.72	-0.85	-0.46	-0.79	-0.25	-0.62		-0.19	-0.46	-1.0	-0.28	-0.24	-0.54	-0.89	-0.81	-0.69	0.81	-0.87	-0.85	-0.5	-0.85	-0.24	-0.89	-0.79
Retained Earnings	-0.24	-0.05	-0.11	-0.24	-0.43	-0.3	-0.69	-0.03	-0.19		-0.24	0.19	-0.68	-0.74	0.19	-0.23	-0.32	-0.34	0.38	-0.24	-0.33	0.01	-0.24	-0.72	-0.24	-0.37
Accounts Payable	0.69	0.91	0.01	0.8	0.93	0.84	0.61	-0.21	-0.46	-0.24		0.46	0.65	0.65	0.33	0.69	0.79	0.71	-0.73	0.75	0.47	-0.33	0.8	0.64	0.69	0.79
Cash	0.89	0.69	0.72	0.84	0.45	0.79	0.25	0.61	-1.0	0.19	0.46		0.27	0.23	0.54	0.89	0.81	0.68	-0.8	0.87	0.85	0.5	0.84	0.24	0.89	0.79
Non Current Assets Total	0.58	0.43	0.01	0.67	0.83	0.68	1.0	-0.14	-0.28	-0.68	0.65	0.27		0.99	0.54	0.57	0.66	0.62	-0.69	0.63	0.48	-0.28	0.67	1.0	0.57	0.7
Non Currrent Assets Other	0.57	0.43	0.02	0.66	0.84	0.68	0.99	-0.13	-0.24	-0.74	0.65	0.23	0.99		0.45	0.56	0.66	0.6	-0.69	0.62	0.49	-0.27	0.66	1.0	0.57	0.7
Other Assets	0.4	0.24	-0.04	0.49	0.4	0.44	0.54	-0.08	-0.54	0.19	0.33	0.54	0.54	0.45		0.4	0.43	0.35	-0.38	0.45	0.26	-0.23	0.49	0.48	0.4	0.41
Cash And Short Term Investments	1.0	0.83	0.69	0.98	0.73	0.96	0.55	0.52	-0.89	-0.23	0.69	0.89	0.57	0.56	0.4		0.96	0.85	-0.98	0.99	0.95	0.39	0.98	0.56	1.0	0.97
Common Stock Total Equity	0.97	0.83	0.56	0.98	0.79	0.99	0.64	0.39	-0.81	-0.32	0.79	0.81	0.66	0.66	0.43	0.96		0.84	-0.97	0.98	0.9	0.23	0.98	0.65	0.96	1.0
Common Stock Shares Outstanding	0.85	0.76	0.48	0.86	0.76	0.85	0.59	0.3	-0.69	-0.34	0.71	0.68	0.62	0.6	0.35	0.85	0.84		-0.87	0.87	0.78	0.19	0.86	0.61	0.85	0.86
Non Current Liabilities Total	-0.98	-0.82	-0.61	-0.98	-0.82	-0.97	-0.67	-0.43	0.81	0.38	-0.73	-0.8	-0.69	-0.69	-0.38	-0.98	-0.97	-0.87		-0.99	-0.93	-0.3	-0.98	-0.68	-0.98	-0.98
Other Current Assets	0.99	0.85	0.61	1.0	0.79	0.98	0.6	0.43	-0.87	-0.24	0.75	0.87	0.63	0.62	0.45	0.99	0.98	0.87	-0.99		0.92	0.3	1.0	0.61	0.99	0.98
Other Stockholder Equity	0.95	0.65	0.85	0.88	0.55	0.87	0.47	0.73	-0.85	-0.33	0.47	0.85	0.48	0.49	0.26	0.95	0.9	0.78	-0.93	0.92		0.62	0.88	0.48	0.95	0.9
Total Liab	0.39	0.01	0.94	0.2	-0.29	0.17	-0.28	0.98	-0.5	0.01	-0.33	0.5	-0.28	-0.27	-0.23	0.39	0.23	0.19	-0.3	0.3	0.62		0.2	-0.27	0.39	0.23
Net Invested Capital	0.98	0.87	0.53	1.0	0.84	0.99	0.64	0.34	-0.85	-0.24	0.8	0.84	0.67	0.66	0.49	0.98	0.98	0.86	-0.98	1.0	0.88	0.2		0.65	0.98	0.99
Property Plant And Equipment Gross	0.57	0.42	0.01	0.65	0.83	0.67	1.0	-0.14	-0.24	-0.72	0.64	0.24	1.0	1.0	0.48	0.56	0.65	0.61	-0.68	0.61	0.48	-0.27	0.65		0.56	0.69
Total Current Assets	1.0	0.82	0.69	0.98	0.73	0.96	0.55	0.52	-0.89	-0.24	0.69	0.89	0.57	0.57	0.4	1.0	0.96	0.85	-0.98	0.99	0.95	0.39	0.98	0.56		0.97
Capital Stock	0.97	0.84	0.56	0.99	0.83	0.99	0.68	0.37	-0.79	-0.37	0.79	0.79	0.7	0.7	0.41	0.97	1.0	0.86	-0.98	0.98	0.9	0.23	0.99	0.69	0.97

Click cells to compare fundamentals

Atea Pharmaceuticals Account Relationship Matchups

Atea Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	22.1M	863.6M	772.9M	666.7M	595.0M	541.8M
Other Current Liab	1.9M	14.4M	49.6M	14.4M	27.4M	20.0M
Total Current Liabilities	2.4M	315.8M	56.9M	18.5M	32.4M	57.0M
Total Stockholder Equity	(49.6M)	547.8M	710.1M	640.6M	555.2M	434.1M
Other Liab	95K	36K	5.9M	5.3M	6.0M	6.3M
Net Tangible Assets	(49.6M)	547.8M	710.1M	640.6M	736.7M	398.8M
Property Plant And Equipment Net	41K	48K	23K	4.1M	3.1M	3.3M
Net Debt	(21.7M)	(850.1M)	(764.2M)	(643.6M)	(141.4M)	(148.5M)
Retained Earnings	(54.2M)	(65.2M)	56.0M	(59.9M)	(195.8M)	(186.0M)
Accounts Payable	548K	60K	4.5M	2.6M	4.3M	2.3M
Cash	21.7M	850.1M	764.4M	646.7M	143.8M	136.6M
Cash And Short Term Investments	21.7M	850.1M	764.4M	646.7M	578.1M	530.8M
Common Stock Shares Outstanding	82.6M	82.4M	88.2M	83.2M	83.4M	85.7M
Liabilities And Stockholders Equity	22.1M	863.6M	772.9M	666.7M	595.0M	541.8M
Non Current Liabilities Total	69.2M	36K	5.9M	7.7M	7.4M	7.0M
Other Current Assets	249K	15.1M	16.1M	14.2M	12.3M	10.7M
Other Stockholder Equity	4.6M	1.5B	654.0M	701.1M	750.7M	658.3M
Total Liab	71.6M	315.8M	62.8M	26.1M	39.8M	78.3M
Net Invested Capital	(49.6M)	547.8M	710.1M	640.6M	555.2M	434.1M
Property Plant And Equipment Gross	41K	48K	184K	4.4M	3.8M	4.0M
Total Current Assets	21.9M	863.5M	772.4M	660.9M	590.5M	539.7M
Net Working Capital	19.5M	547.7M	715.5M	642.4M	558.1M	461.3M
Property Plant Equipment	41K	48K	23K	4.1M	4.7M	4.9M

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Atea Stock

0.68	VALN	Valneva SE ADR	Pair Corr
0.77	FDMT	4D Molecular Therapeutics	Pair Corr
0.76	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.68	LLY	Eli Lilly Sell-off Trend	Pair Corr

Moving against Atea Stock

0.72	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.59	GILD	Gilead Sciences	Pair Corr
0.53	NAMS	NewAmsterdam Pharma	Pair Corr
0.44	LPCN	Lipocine	Pair Corr
0.43	MNOV	MediciNova	Pair Corr

The ability to find closely correlated positions to Atea Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea Pharmaceuticals to buy it.

The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Atea Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Atea Stock Analysis

When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Atea Historical Balance Sheet

About Atea Balance Sheet Analysis

Atea Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Atea Pharmaceuticals balance sheet Correlations

Atea Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Atea Pharmaceuticals balance sheet Accounts

Pair Trading with Atea Pharmaceuticals

Moving together with Atea Stock

Moving against Atea Stock

Additional Tools for Atea Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Other Current Assets	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net

Cash	- 1.0	Net Debt
Other Current Assets	- 0.99	Non Current Liabilities Total
Capital Stock	- 0.98	Non Current Liabilities Total
Total Current Assets	- 0.98	Non Current Liabilities Total
Net Invested Capital	- 0.98	Non Current Liabilities Total
Non Current Liabilities Total	- 0.98	Cash And Short Term Investments